114 related articles for article (PubMed ID: 24432896)
1. Evolving treatment strategies in patients with high-risk acute myeloid leukemia.
Schiller GJ
Leuk Lymphoma; 2014 Nov; 55(11):2438-48. PubMed ID: 24432896
[TBL] [Abstract][Full Text] [Related]
2. Managing acute myeloid leukemia in the elderly.
Melchert M
Oncology (Williston Park); 2006 Nov; 20(13):1674-82; discussion 1683-4, 1687. PubMed ID: 17175744
[TBL] [Abstract][Full Text] [Related]
3. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
Bloomfield CD; Lawrence D; Byrd JC; Carroll A; Pettenati MJ; Tantravahi R; Patil SR; Davey FR; Berg DT; Schiffer CA; Arthur DC; Mayer RJ
Cancer Res; 1998 Sep; 58(18):4173-9. PubMed ID: 9751631
[TBL] [Abstract][Full Text] [Related]
4. Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia?
Larson RA
Best Pract Res Clin Haematol; 2007 Mar; 20(1):29-37. PubMed ID: 17336252
[TBL] [Abstract][Full Text] [Related]
5. Cytogenetic abnormalities and monosomal karyotypes in children and adolescents with acute myeloid leukemia: correlations with clinical characteristics and outcome.
Manola KN; Panitsas F; Polychronopoulou S; Daraki A; Karakosta M; Stavropoulou C; Avgerinou G; Hatzipantelis E; Pantelias G; Sambani C; Pagoni M
Cancer Genet; 2013 Mar; 206(3):63-72. PubMed ID: 23411131
[TBL] [Abstract][Full Text] [Related]
6. Molecular therapy for acute myeloid leukaemia.
Coombs CC; Tallman MS; Levine RL
Nat Rev Clin Oncol; 2016 May; 13(5):305-18. PubMed ID: 26620272
[TBL] [Abstract][Full Text] [Related]
7. Long-term survival of patients with acute myeloid leukemia: a third follow-up of the Fourth International Workshop on Chromosomes in Leukemia.
Bloomfield CD; Shuma C; Regal L; Philip PP; Hossfeld DK; Hagemeijer AM; Garson OM; Peterson BA; Sakurai M; Alimena G; Berger R; Rowley JD; Ruutu T; Mitelman F; Dewald GW; Swansbury J
Cancer; 1997 Dec; 80(11 Suppl):2191-8. PubMed ID: 9395033
[TBL] [Abstract][Full Text] [Related]
8. Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy.
Gupta V; Chun K; Yi QL; Minden M; Schuh A; Wells R; Brandwein J
Cancer; 2005 May; 103(10):2082-90. PubMed ID: 15830348
[TBL] [Abstract][Full Text] [Related]
9. Acute myeloid leukemia in the elderly: a critical review of therapeutic approaches and appraisal of results of therapy.
Ferrara F; Mirto S; Zagonel V; Pinto A
Leuk Lymphoma; 1998 Apr; 29(3-4):375-82. PubMed ID: 9684934
[TBL] [Abstract][Full Text] [Related]
10. Therapy of acute myeloid leukemia: towards a patient-oriented, risk-adapted approach.
Mandelli F; Petti MC; Lo Coco F
Haematologica; 1998 Nov; 83(11):1015-23. PubMed ID: 9864924
[TBL] [Abstract][Full Text] [Related]
11. High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML).
Larson SM; Campbell NP; Huo D; Artz A; Zhang Y; Gajria D; Green M; Weiner H; Daugherty C; Odenike O; Godley LA; Hyjek E; Gurbuxani S; Thirman M; Sipkins D; Van Besien K; Larson RA; Stock W
Leuk Lymphoma; 2012 Mar; 53(3):445-50. PubMed ID: 21913806
[TBL] [Abstract][Full Text] [Related]
12. The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: studies of the Southwest Oncology Group Leukemia Research Program.
Willman CL
Semin Hematol; 1997 Oct; 34(4 Suppl 5):25-33. PubMed ID: 9408958
[TBL] [Abstract][Full Text] [Related]
13. Correlation between CD34 expression and chromosomal abnormalities but not clinical outcome in acute myeloid leukemia.
Fruchart C; Lenormand B; Bastard C; Boulet D; Lesesve JF; Callat MP; Stamatoullas A; Monconduit M; Tilly H
Am J Hematol; 1996 Nov; 53(3):175-80. PubMed ID: 8895688
[TBL] [Abstract][Full Text] [Related]
14. Monosomal karyotype as an adverse prognostic factor in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem-cell transplantation in first complete remission: a retrospective survey on behalf of the ALWP of the EBMT.
Brands-Nijenhuis AV; Labopin M; Schouten HC; Volin L; Socié G; Cornelissen JJ; Huynh A; Ljungman P; Malard F; Esteve J; Nagler A; Mohty M
Haematologica; 2016 Feb; 101(2):248-55. PubMed ID: 26589909
[TBL] [Abstract][Full Text] [Related]
15. Immunophenotyping and cytogenetics in older adults with acute myeloid leukemia: significance of expression of the multidrug resistance gene-1 (MDR1).
Willman CL
Leukemia; 1996 Apr; 10 Suppl 1():S33-5. PubMed ID: 8618468
[TBL] [Abstract][Full Text] [Related]
16. Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study.
Granfeldt Østgård LS; Medeiros BC; Sengeløv H; Nørgaard M; Andersen MK; Dufva IH; Friis LS; Kjeldsen E; Marcher CW; Preiss B; Severinsen M; Nørgaard JM
J Clin Oncol; 2015 Nov; 33(31):3641-9. PubMed ID: 26304885
[TBL] [Abstract][Full Text] [Related]
17. Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup.
Prébet T; Boissel N; Reutenauer S; Thomas X; Delaunay J; Cahn JY; Pigneux A; Quesnel B; Witz F; Thépot S; Ugo V; Terre C; Recher C; Tavernier E; Hunault M; Esterni B; Castaigne S; Guilhot F; Dombret H; Vey N; ; ;
J Clin Oncol; 2009 Oct; 27(28):4747-53. PubMed ID: 19720919
[TBL] [Abstract][Full Text] [Related]
18. The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups.
Schoch C; Kern W; Schnittger S; Büchner T; Hiddemann W; Haferlach T
Haematologica; 2004 Sep; 89(9):1082-90. PubMed ID: 15377469
[TBL] [Abstract][Full Text] [Related]
19. Current and emerging strategies for the management of acute myeloid leukemia in the elderly.
Laubach J; Rao AV
Oncologist; 2008 Oct; 13(10):1097-108. PubMed ID: 18922830
[TBL] [Abstract][Full Text] [Related]
20. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.
Löwenberg B; Suciu S; Archimbaud E; Haak H; Stryckmans P; de Cataldo R; Dekker AW; Berneman ZN; Thyss A; van der Lelie J; Sonneveld P; Visani G; Fillet G; Hayat M; Hagemeijer A; Solbu G; Zittoun R
J Clin Oncol; 1998 Mar; 16(3):872-81. PubMed ID: 9508168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
